Abstract. Pim-1 is a serine/threonine kinase as well as a protooncogene that induces T-cell lymphoma. Pim-1 induces cell cycle progression in cooperation with c-Myc and acts as an inhibitor of apoptotic cell death, actions that are involved in blood cell oncogenesis. However, little is known regarding the role of Pim-1 in oral carcinogenesis. We investigated Pim-1 expression in tongue squamous cell carcinoma (SCC) and examined its clinicopathological features. Western blotting was performed in 6 oral SCC cell lines, with Pim-1 being detected in all 6 of the lines. Immunohistochemical detection of Pim-1 was carried out in 39 cases of tongue SCC and analyzed in terms of its associated clinicopathological features. Pim-1 was expressed in 17/39 cases of tongue carcinoma, and was significantly correlated with lymph node metastasis. The role of Pim-1 in cell motility was further examined in HSC3 cells using the GTP-binding assay for Rho family protein, the motility assay and siRNA treatment. Rac1 activation was observed, and cell motility was reduced when Pim-1 was knocked down by siRNA. These results indicate that Pim-1 is involved in the carcinogenesis of oral SCC and is correlated to metastasis, which is in part associated with the enhancement of cell motility.
Introduction
Squamous cell carcinoma (SCC) is the most common malignant tumor of the oral region (1) , and oral SCC is the sixth most common carcinoma in the world (2, 3) . Patients with oral SCC experience a low quality of life because the disease manifests functional abnormalities of digestion and speech. Moreover, oral SCC has a poor prognosis, with metastasis to regional lymph nodes and/or distant organs.
Pim-1 has been identified as the target of a murine leukemia provirus integration site (4, 5) that induces murine T-cell lymphoma. Human Pim-1, a homologue of murine Pim-1, has been cloned and shown to encode serine/threonine kinase, with a possible role in the neoplastic transformation of blood cells (6) . Pim-1 is an effector of a cytokine signaling pathway, including IFN-Á, G-CSF, GM-CSF and interleukins, and is capable of inducing cell cycle progression by activating Cdc25A in cooperation with c-Myc (7) or by influencing the cellular localization of p21, a cyclin-dependent kinase inhibitor (8) . It also acts as an inhibitor of apoptotic cell death in hematopoietic cells and enhances cell survival with Bcl-2 upregulation (9) and inactivation of the pro-apoptotic BH3 protein Bad (10) . Thus, Pim-1 closely participates in blood cell oncogenesis; however, little is known regarding its role in the carcinogenesis of oral epithelial cells. We investigated Pim-1 expression in tongue SCC, with an emphasis on its clinicopathological features, especially in relation to factors affecting patient prognosis.
The invasive and metastatic potential of cancer cells is likely to affect the prognosis of cancer patients (11, 12) . Thus, to improve prognosis, it is crucial to predict the metastatic potential of cancer cells prior to the initiation of cancer therapy. To date, various factors have been found to be involved in regulating metastasis. A number of these, correlating with cell proliferation, extracellular matrix degradation, cell death resistance, and others, have been considered. The motility of cancer cells is one of the potent factors associated with metastasis. Cytoskeletal filament organization causes the protrusion of the cell structures that induce cell movement. Rho family proteins are known to be involved in this mechanism. Cells in migration show membrane shapes of ruffling and filopodia at the leading edge with, respectively, Rac1 and Cdc42 activation (13, 14) . In the present study, we examined Pim-1 expression and cell motility activity in an oral SCC cell line.
Materials and methods
Cell lines and culture conditions. The human oral SCC cell lines HSC2, HSC3, HSC4, Ca9.22, OSC20 and SAS (JCRB, Osaka, Japan) were used in the study. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Table I . There were 27 male and 12 female patients with a mean age of 62 years (range 35-83 years). TNM classification was conducted according to UICC criteria.
Pim
Immunohistochemical staining. A Pim-1 antibody was used to detect Pim-1 expression in oral carcinomas. Prior to its use in the clinical samples, we validated the ideal condition of the antibody using cell block samples. Pim-1-negative pancreas carcinoma KPN4 and colon carcinoma HCT117 cell lines, which were confirmed to express Pim-1, were harvested, fixed with 10% buffered formalin and embedded in paraffin according to routine histological examination procedures. Formalin-fixed paraffin-embedded tissue blocks were sectioned, dewaxed, rehydrated, and boiled in 10 mM sodium citrate buffer (pH 6.0) for 3 min. Slides were incubated for 5 min in 0.3% hydrogen peroxide followed by 1% BSA for 10 min. They were then exposed to primary rabbit polyclonal antibody for Pim-1 (Calbiochem, Tokyo, Japan) for 1 h at room temperature, followed by exposure to the Histofine Simple Stain PO (R) horseradish peroxidase-conjugated antirabbit secondary antibody (Nichirei, Tokyo, Japan) for 40 min, then washed in PBS. Color was developed by incubation with the EnVision kit/HRP (DAB) (Dako, Tokyo, Japan). The slides were then counterstained with hematoxylin and mounted.
Statistical analysis. The independence of the clinical parameters and histological features (age, gender, tumor size and metastasis) of Pim-1 expression was examined using Fisher's exact test.
siRNA transfection targeting Pim-1. HSC3 cells were transiently transfected with a targeted sequence of Pim-1 siRNA (siPim-1) (Qiagen HP siRNA 1027400) using HiPerfect Transfection Reagent (Qiagen, Tokyo, Japan) according to the manufacturer's protocol. Control sequence siRNA (siControl, Qiagen) was also transfected into HSC3 cells as a negative control. Cells were subjected to immunoblotting and the migration assay after 48 h.
Cell migration assay. HSC3 cells with control siRNA (nc) and siPim-1 were harvested and wounded by scraping. Phasecontrast images were captured at the 0, 1, 4 and 8 h time points, and the width of the cell-free areas was measured. A Boyden chamber (BD-Discovery Labware, Bedford, MA, USA) was also used for the cell migration assay. HSC3 cells with control nc and cells with siPim-1 were seeded into the upper chamber, and EGF was added to the lower chamber as a chemoattractant. After 24 h, the upper surfaces of the filters were wiped with a cotton swab, cells were stained with Giemsa, and the infiltrated cells were counted. All experiments were conducted in triplicate.
Immunoblotting. Cells were lysed in lysis buffer [10 mM Tris-HCl (pH 7.4), 5 mM EDTA, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 0.1% SDS and protease inhibitor cocktail (Roche, Indianapolis, IN, USA)] for 20 min on ice and clarified by microcentrifugation. The supernatant was subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). A Pim-1 rabbit polyclonal antibody (Calbiochem, Tokyo, Japan) was used for Pim-1 detection in cultured oral SCC cell lines. Rac1 and Cdc42 mouse monoclonal antibodies (Upstate, Tokyo, Japan) were employed for the GTP pull-down assay.
GTP pull-down assay. Rac1/Cdc42 activity was analyzed with the Rac/Cdc42 Activation Kit (StressXpress™; Stressgen Bioreagents, Ann Arbor, MI, USA) according to the manufacturer's instructions. In brief, after washing cells were lysed in assay buffer and centrifuged to remove cell debris. To determine total Rac1/ Cdc42 levels, 40 μl of each sample was stored at -80˚C for separate analysis. The remaining 700 μl of the supernatant (containing 500 μg of total protein) was incubated with 10 μg of the agarose-conjugated p21-binding domain of p21-activated protein kinase-1, which binds both activated Rac1 and Cdc42, for 1 h at 4˚C with gentle rocking. Agarose beads that bound active Rac1/Cdc42 were washed 4 times in assay buffer, resuspended in 50 μl of 2X SDS sample buffer, and boiled at 95˚C for 5 min. Active (GTP-bound) and total Rac1/Cdc42 protein levels in each sample were analyzed by Western blotting. All blots were visualized using the ECL Detection System (Amersham Biosciences Corp., NJ, USA).
Results

Pim-1 protein is expressed in oral squamous cell carcinoma cell lines.
To address the role of Pim-1 in oral carcinogenesis, we first examined whether it was expressed in the oral carcinoma cell lines HSC2, HSC3, HSC4, OSC20, Ca9.22 and SAS, analyzed using Western blotting. All cell lines expressed Pim-1 protein, with HSC3 and SAS exhibiting especially high levels. No obvious expression was observed in the normal human gingival fibroblasts used as a negative control (Fig. 1) .
Pim-1 expression in tongue squamous cell carcinomas is related to cancer metastasis.
A total of 39 tongue carcinoma cases were examined. They comprised 11 cases of T1 and 28 cases of T2, 37 cases of N0 and 2 of N2, and 37 cases of M0 and 2 of M1 according to the initial clinical TNM classification. During the follow-up period, subsequent lymph node metastasis occurred in 10 patients, and distant metastasis in 6 of the N0 and M0 cases, respectively. Patient prognoses were as follows: 13 succumbed to their tumors, 2 succumbed to other factors, and 23 are alive without tumors. The prognosis of 1 case is unknown as the patient ceased consulting the hospital during the 5-year follow-up period (Table I ). Prior to addressing the clinical cases, we determined the immunohistochemical detection conditions with cell block materials constructed using a procedure similar to that used for routine pathological specimens. KPN4, a Pim-1-negative pancreas carcinoma cell line, and HCT117, a Pim-1-positive colon carcinoma cell line, were used. No obvious Pim-1-positive signal was observed in KPN4 cells ( Fig. 2A) , but Pim-1 was detected in the nuclei of HCT117 cells (Fig. 2B) under the conditions described in Materials and methods. Immuno-histochemical detection of Pim-1 was performed for 39 tongue SCCs. Nuclear Pim-1-positive signals (Fig. 2C) were observed in 17 of the 39 cases. The remaining 22 were Pim-1 negative. Primary and subsequent lymph node metastases were present in 12 cases, and distant metastasis was observed in 8 cases. Metastasis in the lymph nodes and/or distant organs was observed in 14/39 cases. Among the Pim-1-positive cases, 10/17 exhibited significantly high metastatic activity, whereas among the Pim-1-negative cases only 4/22 did (p<0.005) Table I . Clinicopathological features of the examined cases. Figure 1 . Western blot analysis of Pim-1 expression in oral squamous cell carcinoma cell lines. Pim-1 is observed in 6 oral carcinoma cell lines with slight (HSC2, HSC4, OSC20), moderate (Ca9.22) and high (HSC3, SAS) levels of expression. HGF serves as a negative control. (Fig. 3) . All 10 of the Pim-1-positive and metastasis-burdened patients succumbed to their tumors, whereas 3/22 Pim-1-negative patients experienced a poor clinical course with tumors. No significant association was noted between age or gender and Pim-1 expression.
----------------------------------------------------------------------------------------------------
Pim-1 is associated with cell motility through its activation of
Rac-1. The role of Pim-1 was further explored using HSC3 cells to examine cell motility. siPim-1-transfected HSC3 cells and HSC3 cells transfected with the negative control sequence of siPim-1 (Cont) were used for the experiments. HSC3 cells transiently transfected with siPim-1 exhibited reduced expression of Pim-1 protein (Fig. 4A) . Cell motility was examined by wound-healing and Boyden chamber assays. Repair of the cell monolayer after wounding slowed upon siPim-1 treatment compared to the control (Fig. B) . The width of migrating cells in the scratch wound was significantly narrower in siPim-1-treated HSC3 cells (Fig. 4C) . Furthermore, the migration assay using the Boyden chamber revealed that siPim-1-treated HSC3 cells had an ~50% reduction in motility in comparison to control cells (Fig. 4D) . This difference was statistically significant (p<0.001). Thus, knock-down of Pim-1 extensively suppressed the malignant phenotypes of cell motility in HSC-3 cells.
Next, motility-associated protein expression was examined. The Rho family of GTPases are members of the small G protein family, and change from a GDP-bound inactive form to a GTP-bound active form. In this study, we tested GAP activity using a standard GTPase assay of Rac1 and Cdc42 using immunoprecipitation from HSC3 cells transfected with control siRNA or siRNA for Pim-1. EGF stimulation (100 ng/ml) was conducted to induce cell motility, as HSC3 cells have been shown to possess an EGF receptor that induces cell migration. The GTP-binding assay for Rho family proteins revealed that HSC-3 cells with siRNA for Pim-1 reduced Pim-1 protein expression (siPim-1). EGF stimulation increased the expression of GTP-bound active Rac-1 and Cdc42. Active-Rac-1 expression decreased when cells were treated with siPim-1, although the expression level of Cdc42 was not affected by siPim-1 treatment (Fig. 5) .
Discussion
Pim-1 was originally identified as a proviral integration region of the murine leukemia virus (4), and was shown to be involved in the tumorigenesis of T-cell lymphoma in cooperation with c-Myc (15, 16) . Pim-1 is a serine/threonine kinase, and has been shown to induce cell proliferation via Cdc25A phosphorylation (7) and the inactivation of p21 waf1/cip1 (17) . Pim-1 inhibits apoptotic cell death by inactivating the pro-apoptotic protein Bad and by enhancing Bcl-2 activity (10). These biological featuresare involved in the mechanism of blood cell tumorigenesis, and thus Pim-1 is thought to be a proto-oncogene. Many reports have therefore focussed on the significance of Pim-1 in blood cell tumorigenesis (4, 15, 18, 19) ; however, little is known regarding its role in solid tumors, with the exception of prostate carcinogenesis (20) (21) (22) . We first examined whether Pim-1 was expressed in oral SCC using oral SCC-derived cell lines. It was noted that Pim-1 was In the present study, we investigated Pim-1 expression in patients with tongue SCC. Immunohistochemical detection of Pim-1 in the routine paraffin-embedded biopsy sections from the patients revealed that 17/39 cases were Pim-1-positive and the other 22 Pim-1-negative. These results suggest that Pim-1 expression in tongue SCC is highly correlated with tumor metastasis to the cervical lymph nodes and distant organs. Significantly high metastatic activity was observed in 10/17 Pim-1-positive cases, but in only 4/22 Pim-1-negative cases in the early phase of T1 and T2 tongue SCC. Pim-1 expression was related to a poor prognosis, as all 10 Pim-1-positive and metastasis-burdened patients succumbed to their tumors. Tumor metastatic potential is estimated by histological examination. Poorly differentiated cancers with infiltrative growth are considered to have high metastatic potential. However, unexpected metastasis in tumors that are histologically well differentiated and show expansive growth is sometimes noted. Our results indicate that Pim-1-expressing tongue SCC has latent potential for metastasis, even in histologically lowmalignancy cancers.
Metastasis is a complex process that includes tumor cell invasion of adjacent and vascular tissues, tumor cell dissemination through blood or lymph vessels, escape from apoptosis in anoikis, extravasation from vessels and growth in secondary organs (23) (24) (25) . Tumor cell migration is the essential step of metastasis. Active migration of cancer cells causes intravasation into blood or lymphatic vessels (11, 26, 27) , which is the initial step of the oral SCC metastatic cascade. Cell motility is an important factor in cancer cell migration. Autocrine and paracrine factors, such as hepatocyte growth factor, have also been identified (28) (29) (30) . However, there have been no reports on Pim-1 and cell motility activation. Our results indicate that Pim-1 is closely correlated with cell motility. The knockdown of Pim-1 in HSC3 cells resulted in a significant reduction in motility, confirmed by cell scratch and Boyden chamber assays.
Rho family proteins belong to the Ras superfamily of small GTPases, which are key regulators of cell polarity and motility. Rho, Rac1 and Cdc42 are the main members of the Rho protein family, and Rac1 and Cdc42 can respectively induce cytoplasmic protrusions, known as lamellipodia and filopodia, by stimulating actin polymerization (31) . Rac1 activates the WAVE protein complex that induces Arp2/3 Figure 5 . The active form of Rac-1 is reduced by Pim-1 knockdown. The GTP-binding assay for Rho family proteins revealed that HSC-3 cells with siRNA for Pim-1 reduced Pim-1 protein expression (siPim-1). EGF stimulation (100 ng/ml) increased expression of both GTP-bound active Rac-1 and Cdc42. Active-Rac-1 expression decreased when cells were treated with siPim-1, although the expression level of Cdc42 was not affected by siPim-1 treatment.
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complex-mediated actin polymerization in lamellipodia formation (32) . Cdc42 forms filopodia by activating Dia, which induces actin polymerization in parallel bundles (33, 34) . Both Rac1 and Cdc42 are closely associated with cell motility by altering the structure of the leading edge of the plasma membrane. Rho family proteins bind to GTP and GDP, and these GTP-bound Rho family proteins activate downstream target proteins. Our results reveal that Pim-1 enhances Rac1 activity, which would affect the cytoskeleton filament organization that intermediates cell motility and cause the high metastatic ability of oral SCC.
The present study elucidates the role of Pim-1 in oral SCC. Our results suggest that Pim-1 expression in oral SCC is a predictive factor for metastasis, as it activates cancer cell motility in even the early stages of cancer development. Pim-1 is therefore a promising molecule for gene-targeting therapy.
